- Texas man arrested for powder-letter hoax
- Islamic State opens ‘marriage bureau’ for single jihadists
- Drone almost blocks California firefighting planes
- Tornado rips off roofs, downs trees near Boston
- GOP: Environmental rules keeping agents from accessing border
- John Kerry: Millions displaced by religious fighting in 2013
- Federal appeals court rules against Virginia’s gay marriage ban
- White House says Russia ‘losing’ war in Ukraine
- Hamas turns to North Korea for weapons deal, Iran for money
- Syrian casualties surge as jihadis consolidate
By David Keene
Allowing states to innovate could reduce dependency on bureaucracy
Topic - Mathew Martoma
Lawyers for a former portfolio manager say prosecutors' recommendation that he serve up to 20 years in prison for insider trading is "outrageous" and "irrational."
The former SAC Capital Advisors portfolio manager was convicted Thursday of helping his company earn more than a quarter billion dollars illegally through trades based on secrets about the testing of a potential breakthrough Alzheimer's drug.
A former SAC Capital Advisors portfolio manager was convicted Thursday of helping the company owned by billionaire Steven A. Cohen earn more than a quarter-billion dollars illegally through trades based on secrets about the testing of a potential breakthrough Alzheimer's drug.
An "avalanche of evidence" points to the guilt of a former SAC Capital Advisors hedge fund portfolio manager charged with using inside information to earn his company over a quarter of a billion dollars, a prosecutor told a jury Monday.
An Alzheimer's expert testified Tuesday that he was too ashamed to be truthful when the FBI confronted him with claims he fed inside information to a hedge fund manager whose company owned pharmaceutical stocks.
A former top Alzheimer's researcher told a Manhattan jury Friday that he had to quit teaching at the University of Michigan, because he shared secrets about a drug trial with a hedge fund trader who won him over with some sandwiches and perceptive questions about science and medicine.
A doctor testifying at an insider trading trial told a jury on Tuesday that he revealed secrets about the testing of a drug to treat Alzheimer's disease to a large hedge fund's money manager, who paid him $1,500 an hour for consultations.
NEW YORK (AP) — A former SAC Capital Advisors portfolio manager got inside information about an Alzheimer's drug trial and made a pivotal phone call to his billionaire boss a day before the hedge fund began dumping more than $700 million in pharmaceutical stocks, a prosecutor told a jury Friday in opening statements at the trader's criminal trial.
NEW YORK (AP) — A former money manager facing trial on insider trading charges was expelled from Harvard Law School more than a decade ago after he used a forged transcript he claimed he created to impress his parents to apply for a clerkship with as many as 23 federal appeals judges, according to documents unsealed Thursday.
A former hedge fund portfolio manager accused of enabling a quarter of a billion dollars in profits by passing along inside information in one of the largest insider trading fraud cases in history appeared in a Manhattan court for the first time Monday and was released on $5 million bail, though his movements were restricted.
A former hedge fund portfolio manager was arrested Tuesday on charges that he helped carry out the most lucrative insider trading scheme in U. S. history, enabling investment advisers and their hedge funds to make more than $276 million in illegal profits.
A former hedge fund portfolio manager was arrested Tuesday in what prosecutors called perhaps the most lucrative insider trading scheme of all time _ an arrangement to obtain secret, advance results of tests on an experimental Alzheimer's drug that netted more than $276 million for his fund and others.
The Probation Department recommended Martoma receive from 15.7 to 19.6 years in prison, which would be greater than the record dozen years a former attorney received in Newark, N.J., after he admitted giving secrets during a 17-year insider trading scheme.
He said two doctors agreed to meet, including Dr. Sidney Gilman, who served as chairman of the safety committee overseeing the clinical trial.